593 results about "Diagnostic Reagent" patented technology

The invention provides application of lactic acid modified histone H3 in preparation of drugs and / or diagnostic kits for preventing and / or treating pancreatic ductal adenocarcinoma, and belongs to the technical field of disease diagnosis and / or treatment. The invention provides application of a lactic acid modified histone H3 as a target spot in preparation of a pancreatic ductal adenocarcinoma diagnostic kit or a medicine for preventing and / or treating pancreatic ductal adenocarcinoma. The site of lactic acid modification is 23-site lysine. The expression of H3K23la detected in clinical sample tissues in pancreatic ductal adenocarcinoma tumor tissues is obviously higher than that in para-carcinoma normal tissues, overexpression and non-expression of H3K23la in cells are regulated and controlled through in-vitro experiments in combination with overexpression and knock-down technologies, and results show that proliferation, invasion and migration capacities of pancreatic ductal adenocarcinoma cells are remarkably inhibited, so that the pancreatic ductal adenocarcinoma cells are remarkably inhibited. Therefore, the H3K23la can be used as a target spot for diagnosis and treatment of the pancreatic duct adenocarcinoma, and has wide application in diagnosis or treatment of the pancreatic duct adenocarcinoma.

The invention discloses acinetobacter baumannii and application of the acinetobacter baumannii in construction of a mastitis animal model. The acinetobacter baumannii strain is acinetobacter baumannii AbST3475NMG202308, and the preservation number of the acinetobacter baumannii strain is CGMCC (China General Microbiological Culture Collection Center) No.34450 in the General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms). Experiments prove that the acinetobacter baumannii has high pathogenicity and can be used for establishing a typical animal model caused by acinetobacter baumannii infection, the animal model can be specifically a mastitis animal model, and a certain technical support is provided for subsequent research and development of drugs or vaccines; the acinetobacter baumannii can also be used for screening antibacterial drugs and developing diagnostic reagents and vaccines. The method has an important application value.

The invention provides application of a substance for detecting the ratio of lymphocyte subgroups in preparation of a reagent or a kit for diagnosis or auxiliary diagnosis of Graves disease, and belongs to the technical field of preparation of disease diagnosis reagents. A research shows that compared with a healthy sample, the proportion of B cells in a lymphocyte subpopulation of a to-be-detected sample is remarkably increased, the proportion of NK cells is remarkably reduced, the proportion of activated T cells is remarkably reduced, the proportion of memory T cells is remarkably reduced, the proportion of CD4 + memory T cells is remarkably reduced, the proportion of Th1 cells is remarkably reduced, and the proportion of Tc1 cells is remarkably reduced, so that the to-be-detected sample is a GD patient; the substance for detecting the ratio of lymphocyte subgroups is high in sensitivity and specificity when being used for diagnosis or auxiliary diagnosis of Graves disease.

The utility model discloses a novel protein marker diagnostic kit for detecting the muscle injury degree, which comprises a detection kit for detecting the muscle injury degree and a dustproof cover assembled above the detection kit, the detection kit is provided with a detection port for dropping blood of a patient and a display port for displaying a diagnosis result, a reagent card for evaluating the muscle injury degree by detecting the concentration of a specific protein marker in the blood is arranged in the detection kit, and the detection end of the reagent card is located below the detection port. The display end of the reagent card is positioned below the display opening; a positioning opening for positioning the dustproof cover is formed above the detection kit, and a positioning block matched with the positioning opening is arranged in the dustproof cover. According to the utility model, the muscle injury degree of a patient can be detected by quickly reading the novel protein marker in the blood, so that an accurate diagnosis and treatment basis is provided for the treatment of the patient, the detection time of the patient is shortened, and the treatment cost is reduced.

The invention provides application of AQP1 protein as a target spot in preparation of a diagnostic reagent and a therapeutic drug for hypoglycaemia nephropathy, and belongs to the technical field of biological medicines.The AQP1 protein is used as the target spot, AQP1 protein expression is reduced by adopting an inhibitor, and the hypoglycaemia nephropathy is obtained. According to the present invention, with the application of the kit, the effects of reducing the renal tubule injury markers in the urine, reducing the glomerular filtration rate or relieving the kidney tissue hypoxia can be achieved, the new idea is provided for the early prevention and treatment of the diabetic nephropathy (DKD), and the early recognition and the effective treatment of the kidney injury of the diabetic patient can be well achieved.

A method for automatically generating a research and development proposal for an in vitro diagnostic kit, performed by a server for automatically generating the research and development proposal, includes: acquiring an initial proposal including intended use information for the kit; providing the acquired initial proposal to a pre-trained language model; acquiring a specification (spec) for the kit from the language model receiving the initial proposal, wherein the acquired specification for the kit includes at least one of a technical specification to be used for the research and development of the kit, a resource specification for the research and development, a design specification for the kit, a regulatory approval specification that is needed to meet for approval, and a performance specification for the kit; and controlling to generate the research and development proposal for the kit including the acquired specification and the intended use information for the kit.

The invention belongs to the technical field of gene engineering, and relates to an esophageal squamous cell carcinoma diagnostic kit based on a peripheral blood mononuclear cell methylation marker and application. The kit comprises a primer pair which is used for detecting the methylation of a cg05914150 site, a cg06769875 site, a cg07475126 site, a cg08433285 site, a cg10038907 site, a cg17968322 site, a cg19572487 site, a cg20184330 site, a cg22741248 site and a cg22823192 site. According to the detection kit provided by the invention, the type of a detected sample is peripheral blood, the sample is relatively easy to obtain and non-invasive, and the patient compliance is relatively good. Abnormal methylation changes mostly exist in the early progression process of tumors, early diagnosis of ESCC can be achieved through the methylation detection method provided by the invention, and the five-year survival rate of ESCC patients is effectively increased.

The invention belongs to the technical field of synthesis, and particularly relates to a synthesis method of urea [14C]. The synthesis method of the urea [14C] comprises the following steps: (1) reacting carbonate [14C] with ammonia gas to obtain cyanamide salt [14C]; (2) hydrolyzing the cyanamide salt [14C] obtained in the step (1) with concentrated sulfuric acid at the hydrolysis temperature of 35-45 DEG C; and (3) adjusting the pH value of the hydrolysate obtained in the step (2) with ammonia water, concentrating and purifying to obtain urea [14C]. The synthesis method provided by the invention has the advantages of mild conditions, efficient reaction, high product yield (up to 95% or above), high purity (the chemical purity is greater than or equal to 99%) and the like, and is suitable for large-scale preparation of key raw materials of helicobacter pylori diagnostic reagents.

The invention discloses application of a protein marker CA1 in preparation of a reagent or a kit for early diagnosis of myocardial infarction, and is characterized in that the protein marker is CA1 and a GH1 and CA1 protein combination, and also provides application of the related protein marker in preparation of the reagent or the kit for early diagnosis of myocardial infarction. The kit has the advantages that early-stage AMI diagnosis can be conveniently and quickly realized on the molecular level, the detection efficiency is high, the sensitivity is high, the pertinence is strong, and early-stage discovery and timely treatment of AMI patients are facilitated.

The invention provides a kit for detecting bovine viral diarrhea virus and application of the kit. According to the present invention, the BVDV E2 protein is optimized, the monoclonal antibody 3G5 capable of specifically identifying DVDV1 type and DVD2 type viruses is screened on the basis, and the monoclonal antibody not only can specifically identify the purified and expressed BVDV E2 protein, but also can specifically identify the BVDV in the natural virus infected MDBK cell. By preparing the monoclonal antibody of the BVDV-E2 protein, a series of BVDV immunological diagnostic reagents can be researched and developed, and the monoclonal antibody has important significance on BVDV diagnosis.

The present invention relates to the technical field of genetic engineering. Particularly provided are an identification marker for early chronic obstructive pulmonary disease and the use thereof in a diagnostic kit. The identification marker for the early chronic obstructive pulmonary disease is screened, which is miRNA1255a in serum-derived exosomes; in addition, biological function analysis after sequencing proves that among a plurality of target genes of miRNA1255a, the tissue inhibitor of metalloprotease (TIMP-2) and CD36, which are genes related to the protease / antiprotease balance, are involved in the Ca ion signaling pathway, and moreover, the expression of CD36 and TIMP-2 proteins proves that said two proteins are negatively correlated with miRNA1255a. Moreover, it is found in detection results that the expression of TIMP-2 and the expression of CD36 are all downregulated when the expression of miRNA1255a is upregulated. The biomarker for the early chronic obstructive pulmonary disease is provided, which can easily screen potential patients with early onset of chronic obstructive pulmonary disease.

The invention discloses a 96-hole preassembled plate fat-soluble vitamin pretreatment kit, and belongs to the technical field of in-vitro diagnostic reagents. Comprising magnetic bead suspension liquid, equilibrium liquid, leacheate 1, leacheate 2 and eluent which are carried on a preassembled plate, and the magnetic bead suspension liquid comprises absolute ethyl alcohol and magnetic beads; the preparation process of the magnetic beads comprises the following steps: activating carboxyl of the carboxyl magnetic beads through EDC and NHS; then nitrochlorobenzene and triethylamine are added for a coupling reaction; mixing the coupling reaction product with pyrrolidone, ammonium persulfate and a pore-foaming agent to obtain target magnetic beads; the magnetic beads can be specifically combined with fat-soluble vitamins in human serum or plasma, efficient separation and release of an object to be detected are achieved through a magnetic separation technology, and the magnetic beads are suitable for follow-up mass spectrum quantitative analysis. The kit disclosed by the invention has the characteristics of simplicity and convenience in operation, high extraction efficiency and good stability, the pretreatment time can be remarkably shortened, the detection accuracy is improved, and an efficient solution is provided for clinical detection of fat-soluble vitamins.

The invention relates to a construction method of a nanometer antibody coding DNA library. The method comprises the following steps: screening animal peripheral blood mononuclear cells (PBMC) by using immunogen to obtain positive cells specifically bound with the immunogen; and amplifying a nucleic acid sample derived from the positive cells so as to obtain a coding DNA library of the nano-antibody, wherein the nano antibody is a nano antibody specifically binding to the immunogen, and wherein the amplification comprises the use of one or more groups of primer pairs, each group of primer pairs of the one or more groups of primer pairs comprising one or more forward primers and one or more reverse primers. A large number of diversified DNA sequences covering a large number of low-abundance sequences are obtained. According to the technical route for rapidly preparing the VHH antibody based on high-throughput sequencing, the high-affinity and high-specificity VHH antibody can be efficiently and rapidly obtained, and the raw material requirement of a high-quality diagnostic reagent is met.

The invention discloses an antigen LARP1 of cysticercus bovis and application of the antigen LARP1, and belongs to the technical field of biochemistry. The invention aims to provide a detection method and a treatment and prevention method for cysticercosis bovis. The invention provides an antigen of cysticercus bovis. The amino acid sequence of the antigen of cysticercus bovis is as shown in SEQ ID NO. 4. And a new candidate antigen is provided for research and development of novel vaccines, development of specific diagnostic reagents and the like.

A diagnostic agent for pancreatic cancer, the diagnostic agent comprising: a primer set for amplifying SLC12A7 DNA or mRNA in a sample derived from a subject; and / or a probe that binds to the SLC12A7 DNA, mRNA or an amplification product thereof, or an antibody that binds to SLC12A7 protein. An anti-pancreatic cancer agent comprising an SLC12A7 inhibitor as an active ingredient.

The invention provides an automatic filling production line for an in-vitro detection reagent, which realizes automation of feeding, filling, weighing, film sealing and leakage testing, not only improves the filling efficiency and precision and reduces personal errors, but also saves the cost and time and improves the user experience. The system comprises a reagent bottle feeding and sorting module which comprises a reagent bottle feeding mechanism and a reagent bottle sorting structure; a reagent bottle feeding module; a laser marking and code scanning module; an automatic filling and weighing module; automatic film supply and heat sealing of the film group are realized; an automatic film cutting and waste film collecting module; a leakage test mechanism; a reagent bottle conveying line; and an automatic discharging and transferring module. The reagent bottle conveying line is respectively provided with a plurality of reagent bottle placing racks which are arranged at equal intervals along the length direction of a line body, each reagent bottle is clamped and supported by two side arms of the reagent bottle placing racks from top to bottom, and the reagent bottle conveying line comprises an upper conveying line and a lower return line.

The invention provides an application of a detection reagent of five tryptophan metabolites in preparation of an early diagnosis kit for ER (estrogen receptor) positive breast cancer. The tryptophan metabolites are kynurenine Kyn, indole-3-carboxylic acid glucuronide I3GA, indole-3-acetic acid I3A, indole-3-acetyl-L-alanine IAA-L-Ala and L-tryptophan L-Trp. According to the invention, early accurate diagnosis of ER positive breast cancer is realized, and the technical problems of insufficient efficiency of traditional diagnosis means and lack of'combined application 'in existing metabolite research are solved.

The application belongs to the technical field of biotechnology, and particularly relates to a porcine epidemic diarrhea virus recombinant strain, a construction method and application. The S gene sequence of the existing epidemic porcine epidemic diarrhea virus PEDV CH / SX / 2016 strain is replaced by the S2015 gene sequence shown in SEQ ID NO. 1 to construct a PEDV CH / SX / 2016 strain infectious clone. A porcine epidemic diarrhea virus recombinant strain rCH / SX / 2016-S 2015 is successfully rescued by transfecting cells with a plasmid containing the infectious cDNA shown in SEQ ID NO. 4. The problem that the original strain cannot be successfully rescued by reverse genetics engineering is solved, and the recombinant virus strain rCH / SX / 2016-S 2015 has an activity comparable to that of the original strain, and can be used for preparing a PEDV diagnostic reagent and / or vaccine.

This invention provides a highly pathogenic feline calicivirus strain, its vaccine, and its applications. The highly pathogenic feline calicivirus was isolated from pathogenic material and identified as a highly pathogenic strain, named FCV CC475, with its cDNA sequence shown in SEQ ID NO.1. This strain exhibits strong pathogenicity, causing infected animals to develop symptoms such as fever, paw pad ulcers, and dehydration by day 3 post-infection; the viral load after 5 generations is 10. 9.80 TCID 50 / ml. This strain produces high antibody titers after immunization of cats and rabbits, demonstrating good immunogenicity. Therefore, this highly pathogenic feline calicivirus has broad application prospects in the preparation of feline calicivirus infection vaccines, diagnostic reagents, or therapeutic drugs.

The invention provides a lipoprotein sub-component phospholipid detection kit, and belongs to the field of in-vitro diagnostic reagents, and in particular, the lipoprotein sub-component phospholipid detection kit provided by the invention comprises a reaction reagent, the reaction reagent comprises a buffer solution, a surfactant, magnesium chloride, 4-aminoantipyrine, N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3, 3, 4-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5- The preservative is prepared from 2, 5-dimethoxyaniline sodium salt, phospholipase D, choline oxidase, peroxidase, ascorbic acid oxidase, a protective agent and a third preservative. The lipoprotein subfraction phospholipid detection kit provided by the invention can be used for determining the content of lipoprotein subfraction phospholipid by using a VAP system, simultaneously realizes simultaneous detection of a plurality of lipoprotein subfraction phospholipid items for the first time, and has the advantages of high precision and high accuracy.

The invention discloses an application of a reagent for detecting AP3S2 in preparation of a diagnostic reagent for neoadjuvant immunochemotherapy resistance of gastric cancer in a local progression stage, which comprises the following steps: screening differential expression proteins in neoadjuvant immunochemotherapy resistance tissues of gastric cancer in the local progression stage through proteomics; a new marker is provided for diagnosis of the local progression stage gastric cancer immunochemotherapy drug resistance, and a basis is also provided for development and future development of a local progression stage gastric cancer immunochemotherapy drug resistance diagnosis method.

The invention provides a recombinant herpes simplex virus and a herpes simplex virus modification method. The herpes simplex virus modification method comprises the step of replacing an ICP4 protein coding gene in a herpes simplex virus genome containing an infected cell protein 4 (ICP4) gene with an hTERTp-fluorescent protein expression cassette. The expression cassette comprises an hTERTp promoter and a fluorescent protein coding sequence controlled by the hTERTp promoter, and the transcription direction is opposite to that of an ICP4 promoter in a genome. The hTERTp-fluorescent protein expression cassette in the recombinant virus obtained by the method disclosed by the invention can be normally expressed in response to telomerase activity. Therefore, the recombinant virus is capable of expressing a fluorescent protein, such as mBaoJin, in a cell having human telomerase activity. Cells infected by the virus can be identified through fluorescence signals, and the higher the telomerase activity is, the stronger the fluorescence intensity is. The virus has wide application value in research of tumor action mechanisms and stem cell action mechanisms, health assessment, screening of tumor drugs, research and development of diagnostic reagents and establishment of animal models.

A method for operating and diagnosing faults in a laboratory instrument comprising a plurality of subsystems can include conducting an analysis sequence and a set of diagnostic steps. Such a method can be conducted using diagnostic reagents that contain paramagnetic particles but lack an antibody component. Such a method can also include evaluating a set of instrument subsystems in an order that is opposite to the order in which the subsystems are used during an analysis.

To provide a method of treating a patient with chronic heart failure using a medicament comprising neuregulin.SOLUTION: A companion diagnostic test is first performed on each patient prior to treatment, and the appropriate treatment is provided to each patient according to the companion diagnostic test results. If the test results are within a preferred therapeutic range for treatment, the patient is suitable for treatment of heart failure by administration of an effective amount of neuregulin.SELECTED DRAWING: None

A polyclonal antibody composition specifically binds the pTonB epitope (SEQ ID NO: 11) from Acinetobacter baumannii and is elicited by immunization with a multi-epitope antigen comprising thioredoxin leader, rigid linker, and kernels including SEQ ID NOs: 6, 7, 11, 12, and 8. These antibodies enhance opsonophagocytic killing of A. baumannii Ci79 via classical complement activation and Fey receptor-mediated phagocytosis by bone marrow-derived macrophages. Absorption of pTonB-specific antibodies reduces killing by >70%, confirming epitope dominance. Passive transfer of the composition protects >60% of mice in a lethal intranasal challenge model. Pharmaceutical compositions, treatment methods (alone or with antibiotics like colistin), prophylactic uses, diagnostic kits, and polyclonal compositions are disclosed for combating multidrug-resistant A. baumannii infections.

The application discloses a tandem antigen epitope peptide of G protein of Paralichthys olivaceus rhabdovirus and application thereof, and belongs to the field of fish molecular immunology. The amino acid sequence of the tandem antigen epitope peptide is shown as SEQ ID NO:1. The preparation method of the application comprises the following steps: (1) first, analyzing the structural characteristics of HIRRV-G protein and predicting B cell antigen epitopes, and synthesizing the antigen epitopes with advantages based on the prediction results; (2) then, screening candidate peptide segments with high affinity through enzyme-linked immunosorbent assay; (3) sequentially connecting the high-affinity peptide segment sequences meeting the requirements by using a GPGPG linker, and cloning the connected sequences into a pET-28a prokaryotic expression vector, so that the tandem antigen epitope peptide is obtained after induced expression. Compared with the full-length G protein, the tandem antigen epitope peptide has smaller molecular weight, stronger stability and stronger hydrophilicity; the tandem antigen epitope peptide can induce a large amount of specific antibodies in fish bodies, and significantly reduces the mortality of fish infected by the virus. The tandem antigen epitope peptide can be used for the development of HIRRV diagnostic reagents and subunit vaccines.

This invention relates to the field of biomedical technology, providing the application of glycoprotein tumor biomarkers in the preparation of cancer diagnostic reagents. The glycoprotein tumor biomarker is a CLU_N_291_HexNAc(4)Hex(5) site-specific glycosylation modification. This invention utilizes CLU_N_291_HexNAc(4)Hex(5) site-specific glycosylation modification as a pan-cancer biomarker, combining it with existing conventional tumor markers (CEA, CA19-9, CA50, CA242, CA72-4, CA125, CA15-3, AFP, SCC, CYFRA21-1, PROGRP, NSE, HE-4, or PSA) for early cancer screening, assessment, diagnosis, postoperative monitoring, and / or prognostic analysis, particularly for the diagnosis of pancreatic cancer, cholangiocarcinoma, gastric cancer, lung cancer, breast cancer, or ovarian cancer.

The invention provides a multifunctional compound targeting QC and CB2R and a preparation method and application thereof, the general formula of the chemical structure of the multifunctional compound is shown in the specification, the multifunctional compound can target QC and CB2R proteins and has both QC inhibitory activity and CB2R agonist activity, and a new strategy is provided for treatment of QC and / or CB2R abnormity related diseases. In addition, the invention provides a preparation method of the multifunctional compound, raw materials are easy to obtain, and steps are simple and feasible. Therefore, the multifunctional compound provided by the invention remarkably expands the diversity of molecular structures of compounds targeting QC and CB2R, and can be widely used for preparing medicines, diagnostic reagents and the like for treating diseases related to QC abnormality and / or CB2R abnormality.

The invention discloses a glucose-6-phosphate dehydrogenase mutant as well as an expression strain and application thereof. According to the invention, on the basis of glucose-6-phosphate dehydrogenase from marine microorganisms, after a mutation site is selected by combining Evcouplings design with Fold X scoring, a recombinant plasmid is constructed, and a mutant gene is obtained. After the engineering bacteria containing the mutant plasmids are subjected to induced expression, the glucose-6-phosphate dehydrogenase G6PDH202-Des3 with improved specific enzyme activity is obtained. Under the condition of 37 DEG C, the specific enzyme activity of the mutant is improved to 1.6 times, and the stability is improved to 1.2 times. The mutant has potential application value in an in-vitro diagnostic kit for detecting creatine kinase activity by an enzyme method.

This invention belongs to the fields of molecular biology and bioinformatics, specifically relating to a truncated bovine virus-encoded protein phage library, its construction method, and applications. This library covers all 162 known bovine viruses that host bovine subfamily viruses, containing 51,794 non-redundant peptide coding sequences of 56 amino acids each. These peptides are fused and displayed on the surface of the T7 phage capsid, with all coding sequences having a uniform total length of 200 bp. The library construction was achieved through sequence acquisition, truncation and redundancy removal, codon optimization and DNA synthesis, and in vitro ligation and packaging with T7 phage. The resulting library exhibits a positivity rate of 93% and a titer of 2.8 × 10⁻⁶. 10 PFU / mL. This invention features an optimized single-round high-throughput screening process adapted to clinical bovine serum samples, enabling efficient identification of bovine virus B-cell epitopes and providing tools and candidate targets for bovine virus vaccine development and diagnostic reagent development.